Company profile: Biocytogen
1.1 - Company Overview
Company description
- Provider of integrated solutions for antibody drug development, offering RenMab Mouse for fully human antibody discovery, RenLite for bispecific and multispecific antibody discovery, RenNano for heavy-chain-only antibodies, CRISPR/Cas9 gene editing to create humanized animal models, BioMice genetically modified models, and a bispecific ADC discovery platform targeting multiple tumor proteins.
Products and services
- Bispecific ADC Discovery Platform: Modular system that assembles common light chain mAbs into bispecific antibodies to target multiple tumor proteins, enhancing specificity and reducing toxicity in antibody-drug conjugate development
- RenLite® Mouse: Custom-engineered model for bispecific and multispecific antibody discovery that eliminates chain mispairing issues during development
- RenMab™ Mouse: Research-grade platform for discovering fully human therapeutic antibodies, streamlining the discovery process by eliminating the need for humanization.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biocytogen
Stage Cell Therapeutics
HQ: Germany
Website
- Description: Provider of a proprietary Streptamer platform enabling rapid development and production of safe and efficient cell therapeutics; privately held biotech active since 2005.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stage Cell Therapeutics company profile →
Dicerna
HQ: United States
Website
- Description: Provider of biotechnology research focused on discovering and developing RNA interference (RNAi)-based treatments for rare inherited liver diseases, cancers, and other liver-related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dicerna company profile →
Genewiz
HQ: United States
Website
- Description: Provider of global genomics services, including DNA sequencing, gene synthesis, molecular biology, next-generation sequencing, bioinformatics, and GLP regulatory services. Offerings include GLP-compliant SNP/mutation analysis, plasmid prep, biofluid processing, nucleic acid extraction, integration site analysis for cell and gene therapy, and AAV services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genewiz company profile →
SNIPR Biome
HQ: Denmark
Website
- Description: Provider of CRISPR-based microbial gene therapies that selectively target and eliminate hazardous bacteria without harming beneficial microbes; gut-directed gene therapy via engineered bacteria; CRISPR-Guided Vectors (CGV) for rapid, precise bacterial killing; platforms for in situ therapeutic protein and peptide production; backed by an extensive patent portfolio and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SNIPR Biome company profile →
Fulcrum Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting rare genetic diseases at their root cause, including losmapimod (a small molecule under investigation for facioscapulohumeral muscular dystrophy) and FTX-6058 (a small molecule designed to increase expression of fetal hemoglobin for treating sickle cell disease and beta-thalassemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fulcrum Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biocytogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biocytogen
2.2 - Growth funds investing in similar companies to Biocytogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biocytogen
4.2 - Public trading comparable groups for Biocytogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →